» Articles » PMID: 33512385

T-cell Activation Profiles Distinguish Hemophagocytic Lymphohistiocytosis and Early Sepsis

Abstract

Hemophagocytic lymphohistiocytosis (HLH) is a fatal disorder of immune hyperactivation that has been described as a cytokine storm. Sepsis due to known or suspected infection has also been viewed as a cytokine storm. Although clinical similarities between these syndromes suggest similar immunopathology and may create diagnostic uncertainty, distinguishing them is critical as treatments are widely divergent. We examined T-cell profiles from children with either HLH or sepsis and found that HLH is characterized by acute T-cell activation, in clear contrast to sepsis. Activated T cells in patients with HLH were characterized as CD38high/HLA-DR+ effector cells, with activation of CD8+ T cells being most pronounced. Activated T cells were type 1 polarized, proliferative, and displayed evidence of recent and persistent activation. Circulating activated T cells appeared to be broadly characteristic of HLH, as they were seen in children with and without genetic lesions or identifiable infections and resolved with conventional treatment of HLH. Furthermore, we observed even greater activation and type 1 polarization in tissue-infiltrating T cells, described here for the first time in a series of patients with HLH. Finally, we observed that a threshold of >7% CD38high/HLA-DR+ cells among CD8+ T cells had strong positive and negative predictive value for distinguishing HLH from early sepsis or healthy controls. We conclude that the cytokine storm of HLH is marked by distinctive T-cell activation whereas early sepsis is not, and that these 2 syndromes can be readily distinguished by T-cell phenotypes.

Citing Articles

Cytotoxic T-cell activation profile in critically ill children with malignancies and hemophagocytic lymphohistiocytosis.

Sun S, Liu Y, Zhao H, Miu Y, Huang X, Shen S Pediatr Res. 2025; .

PMID: 40044884 DOI: 10.1038/s41390-025-03962-w.


A predictive model for Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis.

Huang R, Wu D, Wang L, Liu P, Zhu X, Huang L Front Immunol. 2024; 15:1503118.

PMID: 39703509 PMC: 11655318. DOI: 10.3389/fimmu.2024.1503118.


Functional role of UNC13D in immune diseases and its therapeutic applications.

Duong V, Lee D, Kim Y, Oh S Front Immunol. 2024; 15:1460882.

PMID: 39469717 PMC: 11513310. DOI: 10.3389/fimmu.2024.1460882.


Role of DOCK8 in cytokine storm syndromes.

Zhang M, Cron R, Chu N, Nguyen J, Gordon S, Eloseily E J Allergy Clin Immunol. 2024; 155(3):1015-1026.e5.

PMID: 39423879 PMC: 11875994. DOI: 10.1016/j.jaci.2024.10.004.


Immune response to viscerotropic : a comprehensive review.

Lodi L, Voarino M, Stocco S, Ricci S, Azzari C, Galli L Front Immunol. 2024; 15:1402539.

PMID: 39359727 PMC: 11445144. DOI: 10.3389/fimmu.2024.1402539.


References
1.
Machowicz R, Janka G, Wiktor-Jedrzejczak W . Similar but not the same: Differential diagnosis of HLH and sepsis. Crit Rev Oncol Hematol. 2017; 114:1-12. DOI: 10.1016/j.critrevonc.2017.03.023. View

2.
Apel A, Ofran Y, Wolach O, Shimony S, Ram R, Levi I . Safety and efficacy of blinatumomab: a real world data. Ann Hematol. 2020; 99(4):835-838. DOI: 10.1007/s00277-019-03854-0. View

3.
Lin M, Chang H, Huang C, Chen W, Lin C, Lin C . Massive expansion of EBV+ monoclonal T cells with CD5 down regulation in EBV-associated haemophagocytic lymphohistiocytosis. J Clin Pathol. 2007; 60(1):101-3. PMC: 1860609. DOI: 10.1136/jcp.2005.034371. View

4.
Jordan M, Allen C, Greenberg J, Henry M, Hermiston M, Kumar A . Challenges in the diagnosis of hemophagocytic lymphohistiocytosis: Recommendations from the North American Consortium for Histiocytosis (NACHO). Pediatr Blood Cancer. 2019; 66(11):e27929. PMC: 7340087. DOI: 10.1002/pbc.27929. View

5.
Jordan M, Allen C, Weitzman S, Filipovich A, McClain K . How I treat hemophagocytic lymphohistiocytosis. Blood. 2011; 118(15):4041-52. PMC: 3204727. DOI: 10.1182/blood-2011-03-278127. View